167 related articles for article (PubMed ID: 25491283)
1. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Kadlub N; Vazquez MP; Galmiche L; L'Herminé AC; Dainese L; Ulinski T; Fauroux B; Pavlov I; Badoual C; Marlin S; Deckert M; Leboulanger N; Berdal A; Descroix V; Picard A; Coudert AE
J Bone Miner Res; 2015 May; 30(5):878-85. PubMed ID: 25491283
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
3. Defining a new aggressiveness classification and using NFATc1 localization as a prognostic factor in cherubism.
Kadlub N; Sessiecq Q; Dainese L; Joly A; Lehalle D; Marlin S; Badoual C; Galmiche L; Majoufre-Lefebvre C; Berdal A; Deckert M; Vazquez MP; Descroix V; Coudert AE; Picard A
Hum Pathol; 2016 Dec; 58():62-71. PubMed ID: 27498064
[TBL] [Abstract][Full Text] [Related]
4. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
Cheng CP; Sheu MJ; Sytwu HK; Chang DM
Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
[TBL] [Abstract][Full Text] [Related]
5. SH3BP2 is an activator of NFAT activity and osteoclastogenesis.
Lietman SA; Yin L; Levine MA
Biochem Biophys Res Commun; 2008 Jul; 371(4):644-8. PubMed ID: 18440306
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the SH3BP2 gene mutation in cherubism.
Lee JY; Jung YS; Kim SA; Lee SH; Ahn SG; Yoon JH
Acta Med Okayama; 2008 Jun; 62(3):209-12. PubMed ID: 18596838
[TBL] [Abstract][Full Text] [Related]
7. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
8. Pulsed electromagnetic field inhibits RANKL-dependent osteoclastic differentiation in RAW264.7 cells through the Ca
Zhang J; Xu H; Han Z; Chen P; Yu Q; Lei Y; Li Z; Zhao M; Tian J
Biochem Biophys Res Commun; 2017 Jan; 482(2):289-295. PubMed ID: 27856256
[TBL] [Abstract][Full Text] [Related]
9. NFATc1 and TNFalpha expression in giant cell lesions of the jaws.
Amaral FR; Brito JA; Perdigão PF; Carvalho VM; de Souza PE; Gomez MV; De Marco L; Gomez RS
J Oral Pathol Med; 2010 Mar; 39(3):269-74. PubMed ID: 20002873
[TBL] [Abstract][Full Text] [Related]
10. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
11. [The effect of ferric ion on the differentiation of osteoclast and bone resorption].
Jia P; He YF; Gao C; Du HB; Hu ZY; Feng XQ; Li BY; Zhang ZL; Xu YJ; Lin H
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2214-8. PubMed ID: 23158430
[TBL] [Abstract][Full Text] [Related]
12. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
Lietman SA; Yin L; Levine MA
J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
[TBL] [Abstract][Full Text] [Related]
13. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
14. Decreased SH3BP2 inhibits osteoclast differentiation and function.
Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in silico analysis of an inhibitory mechanism of osteoclastogenesis by salubrinal and guanabenz.
Hamamura K; Chen A; Tanjung N; Takigawa S; Sudo A; Yokota H
Cell Signal; 2015 Feb; 27(2):353-62. PubMed ID: 25435425
[TBL] [Abstract][Full Text] [Related]
16. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism.
Aliprantis AO; Ueki Y; Sulyanto R; Park A; Sigrist KS; Sharma SM; Ostrowski MC; Olsen BR; Glimcher LH
J Clin Invest; 2008 Nov; 118(11):3775-89. PubMed ID: 18846253
[TBL] [Abstract][Full Text] [Related]
17. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
18. Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2.
Nakagawa T; Ohta K; Kubozono K; Ishida Y; Naruse T; Takechi M; Kamata N
Arch Oral Biol; 2015 Apr; 60(4):557-65. PubMed ID: 25601046
[TBL] [Abstract][Full Text] [Related]
19. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
